These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 6105801)

  • 21. Suicidal risk in the treatment of outpatient schizophrenics with long-acting neuroleptics.
    Niturad A; Nicholschi-Oproiu L
    Agressologie; 1978; 19(C):145-8. PubMed ID: 35993
    [No Abstract]   [Full Text] [Related]  

  • 22. [Is depot formulation a long-term optimal treatment option?].
    Musch A
    Med Monatsschr Pharm; 2005 Nov; 28(11):414-6. PubMed ID: 16309031
    [No Abstract]   [Full Text] [Related]  

  • 23. Psychopharmacological treatment of schizophrenia.
    Lehmann HE
    Schizophr Bull; 1975; (13):27-45. PubMed ID: 1851
    [No Abstract]   [Full Text] [Related]  

  • 24. Depot antipsychotic medication in the treatment of patients with schizophrenia: (1) meta-review; (2) patient and nurse attitudes.
    David AS; Adams C
    Health Technol Assess; 2001; 5(34):1-61. PubMed ID: 11809126
    [No Abstract]   [Full Text] [Related]  

  • 25. [Experiences with depot-neuroleptics in an after-care unit. Organization of the therapy exemplified with pipotiazine palmitate].
    Salvesen C; Vaksdal K
    Tidsskr Nor Laegeforen; 1973 Aug; 93(24):1699-703. PubMed ID: 4149082
    [No Abstract]   [Full Text] [Related]  

  • 26. Depot antipsychotics in practice. Their rôle in schizophrenia and related psychoses.
    Int Clin Psychopharmacol; 1986 Jul; 1 Suppl 1():1-78. PubMed ID: 2881965
    [No Abstract]   [Full Text] [Related]  

  • 27. [Comparative study of delayed-action neuroleptics in psychiatric therapeutics].
    Pellet J; Guyotat J; Marie-Cardine M; Dubor P; Favre-Tissot M; Caron F; Cottraux J
    J Med Lyon; 1972 Apr; 53(227):591-8. PubMed ID: 4404295
    [No Abstract]   [Full Text] [Related]  

  • 28. [Schizophrenia: prophylaxis prevents recurrence. Low dose depot neuroleptics--an exit from the "revolving door" psychiatry].
    Fortschr Med Suppl; 1993; 147():1-15. PubMed ID: 9260317
    [No Abstract]   [Full Text] [Related]  

  • 29. An atypical long-acting injectable antipsychotic: implications for pharmacotherapy of schizophrenia.
    Dursun S
    J Psychopharmacol; 2005 Sep; 19(5 Suppl):3-4. PubMed ID: 16144780
    [No Abstract]   [Full Text] [Related]  

  • 30. [Results of a survey on the use of delayed-action neuroleptics in psychiatry].
    Bourin M; Venisse JL; Lecuyer F
    Encephale; 1990; 16(5):363-9. PubMed ID: 1979942
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Long-term treatment of outpatients with depot neuroleptics (author's transl)].
    Saameli W
    Schweiz Rundsch Med Prax; 1981 Feb; 70(6):206-10. PubMed ID: 6113584
    [No Abstract]   [Full Text] [Related]  

  • 32. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia.
    Tiihonen J; Haukka J; Taylor M; Haddad PM; Patel MX; Korhonen P
    Am J Psychiatry; 2011 Jun; 168(6):603-9. PubMed ID: 21362741
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Schizophrenia.
    Kane JM
    N Engl J Med; 1996 Jan; 334(1):34-41. PubMed ID: 7494570
    [No Abstract]   [Full Text] [Related]  

  • 34. Oral depot antipsychotic drugs: time for a paradigm shift?
    Nandhra HS; Sule A
    J Ment Health; 2015 Aug; 24(4):181-2. PubMed ID: 25675262
    [No Abstract]   [Full Text] [Related]  

  • 35. [Expert opinion on APAP (prolonged action atypical antipsychotic agents). Position of the pharmacologist. From neuroleptics to non-neuroleptic antipsychotics].
    Costentin J
    Encephale; 2009 Jan; Suppl 3():S119-22. PubMed ID: 19268181
    [No Abstract]   [Full Text] [Related]  

  • 36. Practical considerations in the use of depot neuroleptics for the treatment of schizophrenia.
    Johnson DA
    Br J Hosp Med; 1977 Jun; 17(6):546-58. PubMed ID: 18242
    [No Abstract]   [Full Text] [Related]  

  • 37. [Effects of depot neuroleptics on pituitary hormone secretion (author's transl)].
    Czernik A; Kleesiek K
    Nervenarzt; 1979 Aug; 50(8):527-33. PubMed ID: 43482
    [No Abstract]   [Full Text] [Related]  

  • 38. Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs.
    Kirson NY; Weiden PJ; Yermakov S; Huang W; Samuelson T; Offord SJ; Greenberg PE; Wong BJ
    J Clin Psychiatry; 2013 Jun; 74(6):568-75. PubMed ID: 23842008
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Approaching long-term neuroleptic treatment of schizophrenia.
    Hansell N
    JAMA; 1979 Sep; 242(12):1293-4. PubMed ID: 39181
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-acting injectable formulations of antipsychotic drugs for the treatment of schizophrenia.
    Park EJ; Amatya S; Kim MS; Park JH; Seol E; Lee H; Shin YH; Na DH
    Arch Pharm Res; 2013 Jun; 36(6):651-9. PubMed ID: 23543652
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.